U.S.-based PleoPharma announced yesterday that the FDA has granted it a fast-track designation for PP-01, a new ...
Along with this increase, there has been a jump both in ER visits by people of all age groups who have inadvertently taken ...
A new study shows risks for premature death associated with CUD. Others show increased memory problems, CUD, depression, ...
“If cannabis use ‘causes’ schizophrenia, it is absolutely impossible that the rate of schizophrenia would not be going up ...
A new cohort study found that schizophrenia cases related to cannabis use disorder serious enough to warrant a person to seek emergency care increased afte ...
The proportion of new cases of schizophrenia associated with a cannabis use disorder has risen from 4% pre-legalization to 10 ...
The Food and Drug Administration (FDA) has granted Fast Track designation to PP-01 (nabilone/gabapentin) for the mitigation of cannabis withdrawal ...
The proportion of new cases of schizophrenia associated with a cannabis use disorder has risen from 4% pre-legalization to 10 ...
Schizophrenia cases associated with problematic weed use have skyrocketed in the wake of Canada's legalization of marijuana, ...
New schizophrenia cases linked to cannabis use disorder more than doubled in Ontario after legalisation of drug ...
In people with treatment-resistant depression, investigational inhalable mebufotenin yielded a 15.5-point placebo-adjusted ...
Nevertheless, the authors note that heavy cannabis use does worsen symptoms and the prognosis ... cases associated with a cannabis use disorder over the past 17 years and rising cases of psychosis ...